Compare VRTX & GD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | GD |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Marine Transportation |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 93.8B |
| IPO Year | 2006 | 2006 |
| Metric | VRTX | GD |
|---|---|---|
| Price | $445.47 | $360.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 15 |
| Target Price | ★ $539.69 | $375.33 |
| AVG Volume (30 Days) | ★ 1.1M | 853.7K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.77% |
| EPS Growth | ★ 836.54 | 13.35 |
| EPS | 4.02 | ★ 15.45 |
| Revenue | $2,488,652,000.00 | ★ $52,550,000,000.00 |
| Revenue This Year | $10.79 | $7.38 |
| Revenue Next Year | $10.47 | $4.50 |
| P/E Ratio | $110.19 | ★ $23.27 |
| Revenue Growth | ★ 46.20 | 10.13 |
| 52 Week Low | $362.50 | $275.49 |
| 52 Week High | $509.98 | $369.70 |
| Indicator | VRTX | GD |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 63.80 |
| Support Level | $429.02 | $335.75 |
| Resistance Level | $449.97 | $365.08 |
| Average True Range (ATR) | 10.07 | 6.62 |
| MACD | 0.69 | 1.71 |
| Stochastic Oscillator | 75.17 | 89.10 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments are aerospace, marine, combat systems, and technologies. General Dynamics' aerospace segment manufactures Gulfstream business jets and operates a global aircraft servicing operation. Combat systems produces land-based combat vehicles such as the M1 Abrams tank and Stryker armored personnel carrier, as well as munitions. The marine segment builds and services nuclear-powered submarines, destroyers, and Navy support ships. The technologies segment contains two main units: an IT business that primarily serves the government market and a mission systems business focusing on electronics that provide command, control, computing, intelligence, surveillance, and reconnaissance capabilities to the military.